Quick Search

  Wholesaler/Distributor Registration   l  My Cart   l   My Account  l  Home

 
Brands
  Pharmacist Nutriceuticals®
  USA Best®
  USA LABORATORIES®
  USA SPORTS LABS®
Products
  Health Concerns
  Sexual Health
  Specialty Supplements
  Vitamins & Minerals
  --------------------------------------------
  Weight Loss
  --------------------------------------------
  Children's
  --------------------------------------------
  Female
  Male
  --------------------------------------------
  Sports & Athletic Nutrition
  Extreme Hardcore Body Building
  Body Shaping
  Amino Acids
  Proteins
  Carbohydrates
  --------------------------------------------
  Food Bars
  --------------------------------------------
  Branded Ingredients
  --------------------------------------------
  Press Releases
  --------------------------------------------
  Employment
  Company Policy
X-PLODE® ''The Original'' [click to enlarge]
USAXPV2 - 2.5 lb.

MSRP: $69.99
Internet Direct: $59.99

Bottles:


2.5 lb Creamy Rich French Vanilla
X-PLODE® "The Original"
Dietary Supplement w/X-PLODE® Dilator Factors!

Look imitations are a compliment to USA LABORATORIES® but, we are the original!


Vasodilatation factors (L-Arginine, Arginine alpha keto glutarate, L-citrulline, rutacarpine 95%) 4400 mg †
X-PLODE® Energy Factors:
Calcium citrate, potassium phosphate, L-tyrosine, guarana seed extract,
aspartic acid, green tea leaf extract
1000 mg †
Our Pharmacist packed super ingredients into this uniquely exclusive product.
We've done the work for you and combined into one product every known natural substance that possibly helps raise your strength and performance levels with proper workouts.
This is done by including ingredients that may help boost your own natural output of anabolic testosterone and growth hormone levels.

X-PLODE® "The Original"
2.5 lb Creamy Rich French Vanilla
Dietary Supplement

Look imitations are a compliment to USA LABORATORIES® but, we are the original!

Supplement Facts Serving Size: 1 scoop (25.6 g)
Amount Per Serving % Daily Value
Calories 70
Total Carbohydrate 14 g 5%*
Sugars 0 g †
Niacin (as niacin) 25 mg 125%
Vitamin B6 (as pyridoxine HCl) 10 mg 500%
Folate (as folic acid and methylfolate) 400 mcg 100%
Vitamin B12 (as cyanocobalamin) 500 mcg 8333%
Biotin 25 mcg 8%
Pantothenic acid (as D-calcium pantothenate) 25 mg 250%
Calcium (as calcium citrate and calcium ascorbate) 155 mg 16%
Zinc (as zinc citrate) 5 mg 33%
Copper (as copper citrate) 1 mg 50%
Manganese (as manganese sulfate) 2 mg 100%
Chromium (as chromium picolinate) 50 mcg 42%
Potassium (as potassium phosphate) 200 mg 6%
X-PLODE™ Dilator Factors:
Vasodilatation factors (L-Arginine, Arginine alpha keto glutarate, L-citrulline, rutacarpine 95%) 4400 mg †
X-PLODE™ Energy Factors:
Calcium citrate, potassium phosphate, L-tyrosine, guarana seed extract,
aspartic acid, green tea leaf extract 1000 mg †
* Percent Daily Values are based on a 2,000 calorie diet.
† Daily value not established.
Other Ingredients: Natural and artificial flavors, guar gum, acesulfame potassium, sucralose, red #40. Contains Soy

Directions: Add 1 scoop to 14 oz of cold water and mix well.

* Store at 15-30*C (59-86*F).
* Protect from heat, light and moisture.
* Do not purchase if seal is broken.

Pharmacist References:

L-Carnitine References:
1. Mancini M, Rengo F, Lingetti M, Sorrentino GP, Nolfe G. Controlled study on the therapeutic effica of propionyl-L-carnitine in patients with congestive heart failure. Arzneimittelforschung 1992;42:1101-
2.Giamberardino MA et al. Effects of prolonged L-carnitine adminstration on delayed muscle pain an CK release after eccentric effort. Int J Sports Med 1996;17:320-24.
3. Green RE, Levine AM, Gunning MJ. The effect of L-cartine supplementation on lean body mass male amateur body builders. J AM, Dietet Assoc 1997;(syook):A-72.
4. Murray MT. The many benefits of carnitine. Am J Natural Med 1996;3:6-14 [review].
5. Dal Negro R, Pomari G, et al. L-carnitine and rehabilitative respiratory physiokinesitherapy: metabo and ventilatory response in chronic respiratory insufficiency. Int J Clin Pharmacol Ther Toxicol 1986;24:453-56.
6. Dal Negro R, Turco P, Pomari C, De Conti F. Effects of L-carnitine on physical performance in chronic respiratory insufficiency. Int J Clin Pharmacol Ther Toxicol 1988;26:269-72.
7. Dipalma JR. Carnitine deficiency. Am Family Phys 1988;38:243-51.
8. Kendler BS. Carnitine: an overview of its role in preventive medicine. Prev Med 1986;15:373-90.
9. Del Favero A. Carnitine and gangliosides. Lancet 1988;ii:337 [letter].
10. Kobayashi A, Masumura Y, Yamazaki N. L-carnitine treatment for congestive heart failure-experimental and clinical study. Jpn Circ J 1992;56:86-94.

Pantothenic Acid References:
1. Fidanza A. Therapeutic action of pantothenic acid. Int J Vit Nutr Res 1983;suppl 24-53-67 [review].

Folic Acid References:
1.Daly LE, Kirke PN, Molloy A, et al. Folate levels and neural tube defects. JAMA 1995;274:1698-17.
2. Shaw GM, O'Malley CD, Wasserman CR, et al. Maternal periconceptional use of multivitamins and reduced risk for conotruncal heart defects and limb deciciencies among offspring. Am J Med Gentetics 1995;59:536-45.
3. Tolarova M. Periconceptional supplementation with vitamins and folic acid to prevent recurrence of cleft lip. Lancet 1982;ii:217 [letter].
4. Shaw GM, Lammer EF, Wasserman CR, et al. Risks of orofacial clefts in children born to women using multivitamins containing folic acid periconceptionally. Lancet 14995;345:393-96.
5. Hayes C, Werler MM, Willett WC, Mitchell AA. Case-control study of periconceptional folic acid supplementation and oral clefts. Am J Epidemiol 1996;143:1229-34.
6. Russel RM. A minimum of 13,500 deaths annually from coronary artery disease could be prevented by increasing folate intake to reduce homocysteine levels. JAMA 1996;274:1828-29.
7. Houston DK, Johnson MA, Nozza RJ, et al. Age-related hearing loss, vitamin B-12, and folate in elderly women. Am J Clin Nutr 1999;69:564-71.
8. Butterworth CE Jr, Tamua T. Folic acid safety and toxicity: a brief review. Am J Clin Nutr 1989;50:353-58.
9. Wald NJ, Bower C. Folic acid, pernicious anaemia, and prevention of neural tube defects. Lancet 1994;343:307.
10. Russell RM, Golner BB, Krasinski SD, et al. Effect of antacid and H2 receptor antagonists on the intestinal absorption of folic acid. J Lab Clin Med 1988;112:458-63.
11. Russell RM, Dutta SK, Oaks EV, et al. Impariment of folic acid absorption by oral pancreatic extracts. Dig Dis Sci 1980;25:369-73.

Biotin References:
1. Said HM, Redha R, Nylander W. Biotin transport in the human intestine: Inhibition by anticonvulsar drugs. Am J Clin Nutr 1989;49:127-31.
2. Zempleni J, Mock DM. Biotin biochemistry and human requirements. J Nutr Biochem 1999;10:128-38 [review].
3. Coggeshall JC et al. Biotin status and plasma glucose in diabetics. Ann NY Acad Sci 1985;447:38
4. Koutsikos D. Agroyannis B, Tzanatos-Exarchou H, Biotin for diabetic peripheral neuropathy. Bio Pharmachother 1990;44:511-14.
5. Hochman LG, Scher RK, Meyerson MS. Brittle nails. Responses to daily biotin supplementation. Curtis 1993;51(4):303-5.
6. Gomer E. The Essential Guide to Vitamins and Mineral New York Harger, 1995;70-72.

Paba References:
1. Wiesel LL et al. The synergistic action of para-aminobenzoic acid and cortisone in the treatment of rheumatoid arthritis. Am J Med Sci 1951;222:243-48.
2. Sieve BF. The clinical effects of a new B-complex factor, para-aminobenzioc acid, on pigmentation and fertility. South Med Surg 1942 -March_;104:135-39.
3. Zarafonetis CJD. The treatment of scleroderma: results of potassium para-aminobenzoate therapy 104 cases. In Mills LC, Moyer JH (eds). Inflamation and Diseases of Connective Tissue, W.B. Saunders Co., 1961, 688-96.
4. Zarafonetis CJD et al. Restrospective studies in scleroderma: effect of potassium para-aminobenzoa on survival. J Clin Epidemiol 1988;41:193-205.
5. Zarafonetis CJ, Dabich L, Devol EB, et al. Retrospective studies in scleroderma: pulmonary finding and effect of potassium p-aminobenzoate on vital capacity. Respiration 1989;56:22-33.
6. Clegg DO, Reading JC, Mayes MD, et al. Caparison of aminobenzoate potassium and placebo the treatment of scleroderma. J Rheumatol 1994;21:105-10.
7. Grace WJ et al. Therapy of scleroderma and dermatomyositis. NY State J Med 1963;63:140-44.
8. Zarafonetis CJD, et al. Treatment of pemphigus with potassium para-aminobenzoate. Am J Med S 1956;231:30-50.
9. Sieve BF. Further investigations in the treatment of vitlligo. Virginia Med Monthly 1945 (January):6-17.
10. Hughes CG. Oral PABA and vitiligo. J Am Acad Dermatol 1983;9:770 [letter].
11. Gaby AR. The story of PABA. Nutr Healing 1997;March:3-4, 11 [review].
12. Zarafonetis CJD. Darkening of gray hair during para-amino-benzoic acid therapy. J Invest Derma 1950;15:339-401.
13. Kantor GR, Ratz JL. Liver toxicity from potassium para-aminobenzoate. J Am Acad Dermatol 1985;13:671-2.
14. Worobec S, LaChine A. Dangers of orally administrered para-aminobenzoic acid. JAMA 1984;251:2348.

Choline References:
1. Benjamin J, Levine J. Fux M, et al. Double-blind, placebo-controlled, crossover trial of inositol treatment for panic disorder. Am J Psychiatry 1995;152:1084-86.

Calcium References:
1. Osborne CG, McTyre RB, Dudek J, et al. Evidence for the relationship of calcium to blood pressure Nutr Rev 1996;54:365-81.
2. Barilla DE, Notz C, Kennedy D, Pak CYC. Renal oxalate excretion following oral oxalate loads in patients with ileal disease and with renal and absorptive hypercalciurias: effect of calcium and magnesium. Am J Med 1978;64:579-85.
3. Curhan GC, Willett WC, Rimm EB, Stampfer MJ. A prospective study of dietary calcuim and other nutrients and the risk of symptomatic kidney stones. N Engl J Med 1993;328:833-83.
4. Bell L, Hastenson CE, Halstenson CJ, et al. Cholesterol-lowering effects of calcium carbonate in patients with mild to moderate hypercholesterolemia. Arch Intern Med 1992;152:2441-44.
5. Sheikh MS, Santa Ana CA, Nicar MJ, et al. Gastrointestinal absorption of calcium from milk and calcium salts. N Engle J Med 1987;317:532-36.
6. Levenson DI, Bockman RS. A review of calcium preparations. Nutr Rev 1994;52:221-32 [review].
7. Nicar MJ, Pak CYC. Calcium bioavailabitliy from calcium carbonate and calcium citrate. J Clin Endocrinol Metabol 1985;61:391-93.
8. Harvey JA, Kenny P, Piondexter J, Pak CYC. Superior calcium absorption from calcium citrate that calcium carbonate using external forearm counting. J Am Coll Nutr 1990;9:583-87.
9. Sheikh MS, Santa Ana CA, Nicar MJ, et al. Gastrointestinal absorption of calcium from milk and calcium salts. N Engl J Med 1987;317:532-36.
10. Epstein O, Kato Y, Dick R, Sherlock S. Vitamin D, hydroxyapatite, and calcium gluconate in treatment of cortical bone thinning in postmenopausal women with primary billiary cirrhosis. Am J Clin Nutr 1982;36:426-30.
11. Heaney RP, Recker RR, Weaver CM. Absoubability of calcium sources: the limited role of solubilit Calcif Tissue Int
1990;46:300-4.
12. Deroisy R, Zartarian M, Meurmans L, et al. Acute changes in serum calcium and parathyroid hormone circulating levels induced by the oral intake of five currently available calcium salts in healthy male volunteers. Clin Rheumatol 1997;16:249-53.
13. Levenson DI, Bockman RS. A review of calcium preparatins. Nutr Rev 1994;52:221-32 [review].
14. Burros M. Testing calcium supplements for lead. New York Times June 4, 1997, B7.
15. Bourhoin BP, Evans DR, Cornett JR, et al. Lead content in 70 brands of dietary calcium supplements. Am J Publ Health 1993;83:1155-60.
16. Civitelli R, Villareal DT, Agnusdei D, et al. Dietary L-lysine and calcium metabolism in humans. Nutrition 1992;8:400-5.
17. Flodin NW. The metabolic roles; pharmacology, and toxicology of lysine. J Am Coll Nutr 1997;16:7-21 [review].

Magnesium References:
1. Gaspar AZ, Gasser P, Flammer J. The influence of magnesium on visual field and peripheral vasospasm in glaucoma. Ophthalmologica 1995;209:11-13.
2. Kawano Y, Matsuoka H, Takishita S, Omae T. Effects of magnesium supplementation in hypertens patients. Hypertension 1998;32:260-65.
3. Starobrat-Hermelin B, Kozielec T. The effects of magnesium physiological supplementation on hyperactivity in children with attention deficit hyperactivity disorder (ADHD): Positive response to magnesium oral loading test. Magnesium Res 1997;10:149-56.
4. Cox IM, Campbell MJ, Dowson D. Red boood cell magnesium and chronic fatigue syndrome. Lanc 1991;337:757-60.
5. Howard JM, Davies S, Hunnisett A. Magnesium and chronic fatigue syndrome. Lancet 1992;340:426.
6. Gantz NM. Magnesium and chronic fatigue. Lancet 1991;338:66 [letter].
7. Hinds G, Bell NP, McMaster D, McCluskey DR. Normal red cell magnesium concentrations and magnesium loading tests in patients with chronic fatigue syndrome. Ann Clin Biochem
1994;31(Pt 5):459-61.
8. Weisinger JR, Bellorin-font, E. Magnesium and phosphorus. Lancet 1998;352:391-96 [review].

Zinc References:
1. Mossad SB, Macknin ML, Medendorp SV, et al. Zinc gluconate lozenges for treating the common cold. Ann Int Med 1996;125:81-88.
2. Anonymous. Zinc lozenges reduce the duration of common cold symptoms. Nutr Rev 1997;55:82-88 [review].
3. Garland ML, Hagmeyer KO. The role of zinc lozenges in treatment of the common cold. Ann Pharmacother 1998;32:63-69 [review].
4. Macknin ML, Piedmonte M, Calendine C, et al. Zinc gluconate lozenges for treating the common cold in children. A randomized controlled trial. JAMA 1998;279:192-67.
5. Eby G. Where's the bias? Ann Intern Med 1998;128:75 [letter].
6. Petrus EJ, Lawson KA, Bucci LR, Blum K. Randomized, double-masked, placebo-controlled clinical study of the effectiveness of zinc acetate lozenges on common cold symptons in allergy-tested subjects. Curr Ther Res 1998;59:595-607.
7. Weismann K, Jakobsen JP, Weismann JE, et al. Zinc gluconate lozenges for common cold. A double-blind clinical trial. Dan Med Bull 1990;37:279-81.
8. Cherry FF, Sandstead HH, Rojas P, et al. Adolescent pregnancy: associations among body weight, zinc nutriture, and pregnancy outcome. Am J Clin Nutr 1989;50:945-54.
9. Goldenberg RL, Tamura T, Neggers Y, et al. The effect of zinc supplementation on pregnancy outcome. JAMA 1995;274:463-68.
10. Prasad A. Discovery of human zinc deficiency and studies in an experimental human model. Amer clin Nutr 1991;53:406-13 [review].
11. Chandra RK. Excessive intake of zinc impairs immune responses. JAMA 1984;252(11):1443.
12. Bush Al, Pettingell WH, Multhaup G, et al. Rapid induction of Alzheimer A8 amyloid formation by zinc. Science 1994;265:1464-65.
13. Potocnik FCV, van Rensburg SJ, Park C, et al. Zinc and platelet membrane microviscosity in Alzheimer's disease. S Afr Med J 1997;87:1116-19.
14. Prasad AS. Zinc in human health: an update. J Trace Elements Exper Med 1998;11:63-87.
15. Broun ER, Greist A, Tricot G, Hoffman R. Excessive zinc ingestion-a reversible cause of sideroblastic anemia and bone marrow depression. JAMA 1990;264:1441-43.
16. Resiser S, et al. Effect of copper intake on blood colesterol and its lipoprotein distribution in men. Nutr Rep Internat 1987;36(3):641-49.
17. Sandstead HH. Requirements and toxicity of essential trace elements, illustrated by zinc and copper. Am Jclin Nutr 1995;61(suppl):621S-24S [review].
18. Fischer PWF, Girous A, Labbe MR. Effect of zinc supplementation on copper status in adult man. Am J Clin Nutr 1984;40(4):743-46.
19. Dawson EB, Albers J, McGanity WJ. Serum zinc change due to iron supplementation in teenage pregnancy. Am J Clin Nutr 1990;50:848-52.
20. Crofton RW, Gvozdanovic D, Gvozanovic S, et al. Inorganic zinc and the intestinal absorption of ferrous iron. Am J Clin Nutr 1989;50:141-44.
21. Argiratos V, Samman S. The effect of calcium carbonate and calcium citrate on the absorption of zinc in healthy female subjects. Eur J Clin Nutr 1994;48:198-204.
22. Spence H, Norris C, Williams D. Inhibitory effects of zinc on magnesium balance and magnesium absorption in man. J Am Coll Nutr 1994;13:479-84.
23. Brumas V, Hacht B, Filella M, Berthon G. Can N-acetyl-L-cysteine affect zinc metabolisms when used as a paracetamol antidote? Agents Actions 1992;36:278-88.

Copper References:
1. Sandstead HH. Requirements and toxicity of essential trace elements, illustrated by zinc and copper Am J Clin Nutr 1995;61(suppl):62S-64S.
2. Broun ER. Greist A, Tricot G, Hoffman R. Excessive zinc ingestion. A reversible cause of siderobla anemia and bone marrow depression. JAMA 1990;264:1441-43.
3. Jacob RA, Skala JH, Omaye ST, Turnlund JR. Effect of varying ascorbic acid intakes on copper absorption and ceruloplasmin levels of young men. J Nutr 1987;117:2109-15.

Chromium References:
1. Saner G, Yüzbasiyan V, Neyzi O, et al. Alterations of chromium metabolism and effect of chromium supplementation in Turner's syndrome patients. Am J Clin Nutr 1983;38:574-78.
2. Riales R, Albrink MJ. Effect of chromium chloride supplementation on glucose tolerance and serum lipids including high-density lipoprotein of adult men. Am J Clin Nutr 1981;34:2670-78.
3. Wang MM, Fox EZ, Stoecker BJ, et al. Serum cholesterol of adults supplemented with brewer's yeast or chromium cholride. Nutr Res 1989;9:989-98.
4. Page TG, Ward TL, and Southern LL. Effect of chromium picolinate on growth and carcass characteristics of growing-finishing pigs. J Animal Sci 1991;69:356.
5. Lefavi R, Anderson R, Keith R, et al. Efficacy of chromium supplementation in athletes: Emphasis on anabolism. Int J Sport Nutr 1992;2:111-22.
6. McCarty MF. The case for supplemental chromium and a survey of clinical studies with chromium picolinate. J Appl Nutr 1991;43:59-66.
7. Hallmark MA, Reynolds TH, DeSouza CA, et al. Effects of chromium and resistive training on muscle strength and body composition. Med Sci Spt Ex 1996;28:139-44.
8. Kaats GR, Blum K, Fisher JA, Adelman JA. Effects of chromium picolinate supplementation on body composition: a randomized, double-masked, placebo-controlled study. Curr Ther Res 1996;57:747-51.
9. Kaats GR, Blum K, Pullin D, Keither SC, Wood R. A randomized, double-masked, placebo-control study of the effects of chromium picolinate supplementation on body composition: a replication and extension of a previous study. Curr Ther Res 1998;59:379-88.
10. Sterns DM, Belbruno JJ, Wetterhahn KE. A prediction of chromium (III) accumulation in humans from chromium dietary supplements. FASEB J 1995;9:1650-57.
11. Sterns DM, Wise JP, Patierno SR, Wetterhahn KE. Chromium (III) picolinate produces chromosl damage in Chinese hamster ovary cells. FASEB J 1995;9:1643-49.
12. Garland M, Morris JS, Colditz GA, et al. Toenail trace element levels and breat cancer. AmJ Epidemiol 1996;144:653-60.
13. Cerulli J, Grabe DW, Guathier I, et al. Chromium picolinate toxicity. Ann Pharmacother 1998;32:428-31.
14. Wasser WG, Feldman NS. Chromic renal failure after ingestion of over-the-counter chromium picolinate. Ann Intern Med 1997;126:410 [letter].
15. Offenbacher EG. Promotion of chromium absorption by ascorbic acid. Trace Elements Electrolyte 1994;11:178-81.

Molybdenum References:
1. Johnson JL et al. Molybdenum cofactor deficiency in a patient previously characterized as deficient sulfite oxidase. Biochem Med Metabol Biol 1988;40:86-93.

Selenium References:
1. Clark LC, Combs FG, Turnbull BW, et al. Effects of selenium supplementation for cancer prevention in patients with carcinoma of the skin. JAMA 1996;276:1957-63.
2. Yoshizawa K, Willett WC, Morris SJ, et al. Study of prediagnostic selenium levels in toenails and the risk of advanced prostate cancer. J Natl Cancer Inst 1998;20:15-20.
3. Yu S-Y, Li W-G, Zhu Y-J, et al. Chemoprevention trial of human hepatitis with selenium supplementation in China. Biol Trace Element Res 1989;20:15-20.
4. Peretz A, Neve J, Desmedt J, et al. Lymphocyte response is enhanced by supplementation of elderly subjects with selenium-enriched yeast. Am J Clin Nutri 1991;53:1323-28
5. Scott R, Macpherson A, Yates RWS, et al The effects of oral selenium supplementation on human sperm motility. Br J Urol 1998;82:76-80.
6. Dworkin BM. Selenium deficiency in HIV infection and the acquired immunodeficiency syndrome (AIDS). Chem Biol Iteract 1994;91:181-86.
7. Moore JA, Noiva R, Wells IC. Selenium concentractions in plasma of patients with arteriographically defined coronary atherosclerosis. Clin Chem 1984;30:1171-73.
8. Contempre B, Dumont JE, Ngo B, et al. Effects of selenium supplementation in hypothyroid subjects of an iodine and selenium deficient area: The possible danger of indiscriminate supplementation of iodine deficient subjects with selenium. J Clin Endocrinol Metabol 1991;73:213-15.

Manganese References:
1. Raloff J. Reasons for boning up on manganese. Science Sep 1986, 199 [review].
2. Krieger D, Kreiger S, Jansen O, et al. Manganese and chronic hepatic encephalopathy. Lancet 1995;346:270-74.
3. Freeland-Graves JH. Manganese: an essential nutrient for humans. Nutr Today 1989;23:13-19 [review].


  • Back To List
  • Wholesaler/Distributor Registration   l  My Cart   l   My Account  l  Home  l  Return to Top of Page

        Nasvhille Chamber of Commerce Dickson County Chamber of Commerce U.S. Commercial Service

    *These statements have not been evaluated by the F.D.A. *USA Laboratories makes no representation or warranties concerning the use of our products for the diagnosis, cure, mitigation, treatment or prevention of any disease. *Seek advice from a health care provider before using this or any supplement product.

    Powered By LionZone Copyright © USA LABORATORIES, INC. All rights reserved.